Verona Pharma has a pleasing habit of delivering important trial results on schedule, and this morning’s announcement, confirming the completion of recruitment in the Phase IIb trial of nebulised ensifentrine in moderateto-severe COPD, is no exception. We continue to look forward to data from the 416-patient, 46-centre trial around year-end, to be followed by an end-of-Phase II meeting with the FDA in H1 2020e and the start of Phase III trials in 2020, in line with previous guidance. Po ....